beta
/Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Reviews

Join the dialogue

Submit a peer review to improve the scientific record

Summary